A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Endometrial cancer; Prostate cancer
- Focus Adverse reactions
- 04 Jun 2019 According to an abstract presented at the 55th Annual Meeting of the American Society of Clinical Oncology, 4 patients have been enrolled to the study.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 16 May 2019 According to a Clovis Oncology media release, data from this trial will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 to June 4 in Chicago.